

Vaccines for Adults at Risk

Vaxneuvance & Prevnar 20 are Now Available

Vaxneuvance (15-valent pneumococcal conjugate vaccine, PCV15) and Prevnar 20 (20-valent pneumococcal conjugate vaccine, PCV20) are now available through the Vaccines for Adults at Risk (VFAAR) program. This advisory includes an overview of important information about Vaxneuvance and Prevnar 20.

Vaxneuvance is a vaccine indicated for active immunization for the prevention of invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults.

Prevnar 20 is a vaccine indicated for active immunization for the prevention of pneumonia and invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults.

In 2021, Vaxneuvance and Prevnar 20 were licensed by the Food and Drug Administration for adults. On October 20, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended use of either PCV20 alone or PCV15 in series with PPSV23 for all adults aged ≥ 65 years, and for adults aged 19–64 years with certain underlying medical conditions or other risk factors, who have not previously received a PCV or whose previous vaccination history is unknown.

Recommendations For Use

Eligible Groups for Receipt of VFAAR Supplies of Vaxneuvance (PCV15) and Prevnar 20 (PCV20)

VFAAR supplies of Vaxneuvance and Prevnar 20 may be given to VFAAR-eligible individuals, 19 years of age and up, based on underlying medical conditions or other risk factors and history of vaccination.

Adults aged ≥ 65 years. Adults aged ≥ 65 years who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23 (Table 1).

Adults aged 19–64 years with certain underlying medical conditions or other risk factors. Adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23.

Clinical Guidance

Dosing schedule. When PCV15 is used, the recommended interval between administration of PCV15 and PPSV23 is ≥ 1 year. A minimum interval of 8 weeks can be considered for adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak to minimize the risk for IPD caused by serotypes unique to PPSV23 in these vulnerable groups.

Adults with previous PPSV23 only. Adults who have only received PPSV23 may receive a PCV (either PCV20 or PCV15) ≥ 1 year after their last PPSV23 dose. When PCV15 is used in those with history of PPSV23 receipt, it need not be followed by another dose of PPSV23.

Adults with previous PCV13. The incremental public health benefits of providing PCV15 or PCV20 to adults who have received PCV13 only or both PCV13 and PPSV23 have not been evaluated. These adults should complete the previously recommended PPSV23 series. For adults who have received PCV13 but have not completed their recommended pneumococcal vaccine series with PPSV23, one dose of PCV20 may be used if PPSV23 is not available.

Coadministration with other vaccines. PCV15, PCV20, or PPSV23 can be co-administered with QIV in an adult immunization program, as concomitant administration (PCV15 or PPSV23 and QIV [Fluarix], PCV20 and adjuvanted QIV [Fluad]) has been demonstrated to be immunogenic and safe. However, slightly lower pneumococcal serotype-specific OPA GMTs or geometric mean concentrations were reported when pneumococcal vaccines were co-administered with QIV compared with when pneumococcal vaccines were given alone. Currently, no data are available on coadministration with other vaccines (e.g., tetanus, diphtheria, acellular pertussis vaccine, hepatitis B, or zoster vaccine) among adults. Evaluation of coadministration of PCV15, PCV20, or PPSV23 with COVID-19 vaccines is ongoing.

Vaccines for Adults at Risk

Vaxneuvance & Prevnar 20 are Now Available

Licensed Dosing Schedule

Recommendations for use of 15-valent pneumococcal conjugate vaccine in series with 23-valent pneumococcal polysaccharide vaccine or 20-valent pneumococcal conjugate vaccine in pneumococcal conjugate vaccine-naïve adults aged ≥ 19 years

Medical indication group	Specific underlying medical condition	Ages 19-64	Ages ≥ 65
None	None	None	1 dose of PCV20 or 1 dose of PCV15 followed by a dose of PPSV23 ≥ 19 years later*
Underlying medical conditions or other risk factors	Alcoholism Chronic heart disease† Chronic liver disease Chronic lung disease¶ Cigarette smoking Diabetes mellitus Cochlear implant CSF leak Congenital or acquired asplenia Sickle cell disease or other hemoglobinopathies Chronic renal failure** Congenital or acquired immunodeficiencies*** Generalized malignancy** HIV infection** Hodgkin disease** Iatrogenic immunosuppression**§§ Leukemia** Lymphoma** Multiple myeloma** Nephrotic syndrome** Solid organ transplant**	1 dose of PCV20 or 1 dose of PCV15 followed by a dose of PPSV23 ≥ 1 years later§	1 dose of PCV20 or 1 dose of PCV15 followed by a dose of PPSV23 ≥ 1 years later*

Abbreviations: CSF = cerebrospinal fluid; PCV15 = 15-valent pneumococcal conjugate vaccine; PCV20 = 20-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.

* Adults with immunocompromising conditions, cochlear implant, or CSF leak might benefit from shorter intervals such as ≥ 8 weeks. These vaccine doses do not need to be repeated if given before age 65 years.

† Includes congestive heart failure and cardiomyopathies.

§ Adults with immunocompromising conditions, cochlear implant, or CSF leak might benefit from shorter intervals such as ≥ 8 weeks.

¶ Includes chronic obstructive pulmonary disease, emphysema, and asthma.

** Indicates immunocompromising conditions.

†† Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).

§§ Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.

Vaccines for Adults at Risk

Vaxneuvance & Prevnar 20 are Now Available

Storage

Vaxneuvance and Prevnar 20 should be stored at 2° to 8°C (36° to 46°F). Do not freeze. Product which has been exposed to freezing should not be used. Do not use after the expiration date shown on the label.

How Vaxneuvance and Prevnar 20 are supplied

Vaxneuvance and Prevnar 20 are supplied as single-dose pre-filled syringes in packages of 10 doses (Vaxneuvance, NDC no. 00006-4329-03 and Prevnar 20, NDC no. 00005-2000-10). The dosage for Vaxneuvance is 0.5 mL, the dosage for Prevnar 20 is 0.5 mL. Neither vaccine contains a preservative. The vial stopper, syringe plunger stopper, and syringe tip cap are not made with natural rubber latex.

Administration

Just before use, shake the syringe until a uniform, white, cloudy suspension results.

Inspect the syringe for particulate matter and discoloration prior to administration. If either of these conditions exist, the product should not be administered.

Administer a single 0.5 mL dose of Vaxneuvance or Prevnar 20 intramuscularly.

Ordering and Billing

Vaxneuvance and Prevnar 20 will be available for ordering through the PhilaVax IIS as of, Tuesday, April 12, 2022.

Vaxneuvance

CVX code: 215 CPT code: 90671

Prevnar 20

CVX code: 216 CPT code: 90677

VFAAR sites must decide whether they will order PCV20 or PCV15 and PPV23 going forward. Scan the adjacent QR code to complete a survey to notify our program your site preference. We will review each site's submission and reach out with next steps.

We recommend that sites that are part of a system or are affiliated use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.



TAKE OUR SURVEY!


Resources

MMWR




<https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm>

Vaxneuvance package insert




<https://www.fda.gov/media/150819/download>

Prevnar 20 package insert



<https://www.fda.gov/media/149987/download>

Vaccine Information Statement (VIS)



<https://www.immunize.org/vis/pcv.pdf>

Immunize.org



https://www.immunize.org/askexperts/experts_pneumococcal_vaccines.asp#rec_adult